EFFECTS OF DOSE, PH AND OSMOLARITY ON INTRANASAL ABSORPTION OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN RATS

被引：0

作者：

SHIMODA, N ^{[1
]}

MAITANI, Y ^{[1
]}

MACHIDA, Y ^{[1
]}

NAGAI, T ^{[1
]}

机构：

[1] CHUGAI PHARMACEUT CO LTD, DEPT BUSINESS COORDINAT, DIV DEV & TECHNOL, KITA KU, TOKYO 115, JAPAN

来源：

BIOLOGICAL & PHARMACEUTICAL BULLETIN | 1995年 / 18卷 / 05期

关键词：

ERYTHROPOIETIN; INTRANASAL ADMINISTRATION; GLYCOPROTEIN CIRCULATING RETICULOCYTE; BIOAVAILABILITY;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The effects of dose, pH and osmolarity on the intranasal absorption of a recombinant human erythropoietin (rEPO) solution were studied in male Wistar rats, The intranasal administration of rEPO was evaluated by measuring percentage circulating reticulocytes of red blood cells on a stained blood smear (smear method), and also by measuring residual circulating reticulocyte counts using a microcell counter (sysmex method), Both results suggest that rEPO solution was absorbed through the nasal mucosa of rats without enhancers after a single intranasal administration, The pharmacological availabilities of rEPO after intranasal administration compared with intravenous administration were about 7% and 4%, when estimated by smear method and sysmex method, respectively, The pharmacological activity was enhanced in low pH and hypotonic mannitol solution.

引用

页码：734 / 739

页数：6

共 50 条

[21] RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHEPO) ADMINISTRATION MARROW DONORS [J].

AKIYAMA, H ;

TANIKAWA, S ;

TAKAMOTO, S ;

SAKAMAKI, H ;

SASAKI, T ;

ONOZAWA, Y .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 1995, 62 (03) :145-149

[22] EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON HUMAN IGE PRODUCTION INVITRO [J].

KIMATA, H ;

YOSHIDA, A ;

ISHIOKA, C ;

MIKAWA, H .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1991, 83 (03) :483-487

[23] RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND MYELOFIBROSIS [J].

MOHR, B ;

HERRMANN, R ;

HUHN, D .

ACTA HAEMATOLOGICA, 1993, 90 (02) :65-70

[24] IS RECOMBINANT-HUMAN-ERYTHROPOIETIN TREATMENT IN MYELODYSPLASTIC SYNDROMES WORTHWHILE [J].

SPIRITI, MAA ;

PETTI, MC ;

LATAGLIATA, R ;

AVVISATI, G ;

DEGREGORIS, C ;

PROIA, S ;

FAZI, P ;

JAALOUK, G ;

MANCINI, M ;

SPADEA, A ;

VILLA, R ;

MANDELLI, F .

LEUKEMIA & LYMPHOMA, 1993, 9 (1-2) :79-83

[25] THE LONG-TERM EFFECTS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON THE CARDIOVASCULAR-SYSTEM [J].

ESCHBACH, JW ;

AQUILING, T ;

HALEY, NR ;

FAN, MH ;

BLAGG, CR .

CLINICAL NEPHROLOGY, 1992, 38 :S98-S103

[26] RECOMBINANT-HUMAN-ERYTHROPOIETIN IN THE TREATMENT OF INFANTS WITH ANEMIA OF PREMATURITY [J].

HALPERIN, DS ;

FELIX, M ;

WACKER, P ;

LACOURT, G ;

BABEL, JF ;

WYSS, M .

EUROPEAN JOURNAL OF PEDIATRICS, 1992, 151 (09) :661-667

[27] THERAPY WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES [J].

STONE, RM ;

BERNSTEIN, SH ;

DEMETRI, G ;

FACKLAM, DP ;

ARTHUR, K ;

ANDERSEN, J ;

ASTER, JC ;

KUFE, D .

LEUKEMIA RESEARCH, 1994, 18 (10) :769-776

[28] RECOMBINANT-HUMAN-ERYTHROPOIETIN AND THE ANEMIA OF MULTIPLE-MYELOMA [J].

BARLOGIE, B ;

BECK, T .

STEM CELLS, 1993, 11 (02) :88-94

[29] EFFECTIVENESS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY IN MYELODYSPLASTIC SYNDROMES [J].

ADAMSON, JW ;

SCHUSTER, M ;

ALLEN, S ;

HALEY, NR .

ACTA HAEMATOLOGICA, 1992, 87 :20-24

[30] USE OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN A JEHOVAH-WITNESS [J].

KOENING, HM ;

LEVINE, EA ;

RESNICK, DJ ;

MEYER, WJ .

JOURNAL OF CLINICAL ANESTHESIA, 1993, 5 (03) :244-247

← 1 2 3 4 5 →